Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?
Patients with advanced breast cancer who:
COHORT A SPECIFIC ELIGIBILITY CRITERIA:
COHORT B SPECIFIC ELIGIBILITY CRITERIA:
The study is being conducted by researchers at Stanford University Hospital. Contact Pei Jen Chang by phone at 310-967-4339 or by email.
The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information.
The study is open to people with advanced breast cancer. There are two cohorts both of which will receive the same treatment.
This study is not open to people with a BRCA1 or BRCA2 mutation.
This is an open-label, single-arm study.
Melinda Telli, MD: Stanford University Hospital